Vaccinex, Inc. Appoints Elizabeth Evans as Chief Operating Officer
May 17, 2021 at 08:15 am
Share
On May 11, 2021, Vaccinex, Inc.'s Board of Directors appointed Elizabeth Evans to serve as the company's Chief Operating Officer. Prior to her appointment as the Chief Operating Officer, Ms. Evans has served the Company since May 2001 in a series of roles of increasing responsibility, including as its Senior Vice President, Discovery and Translational Medicine from March 2020 to May 2021, its Vice President, Discovery Research from March 2019 to March 2020, its Vice President, Preclinical Research from July 2016 to March 2019, and its Director, Oncology Research from December 2013 to July 2016.
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimerâs disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.